NOV 26, 2020 7:30 AM PST

Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers

WRITTEN BY: Tara Fernandez

There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanoparticles that stimulate the immune system to eliminate tumors. Tumors often metastasize to the lungs via the circulatory system, where they shield themselves from circulating immune cells by secreting immunosuppressive chemicals. These metastatic cells then form secondary tumors in the lungs of advanced-stage cancer patients.

Scientists at Harvard’s Wyss Institute have devised a therapeutic system to combat this by leveraging the help of the body’s own immune defenses.

“Our approach is the exact opposite of conventional cancer treatments that focus on getting the immune system to recognize and attack the primary tumor, because those tumors are often large and difficult for immune cells to penetrate,” said Zongmin Zhao, one of the researchers involved in the study. 

“We recognized that the high density of blood vessels in the lungs provides much better access to tumors there, offering a unique opportunity to induce an immune response by targeting the metastasis.”

The researchers called the platform the so-called EASI system, with the nanoparticles that latch on to red blood cells known as “ImmunoBait”. The bait here is an inflammatory chemokine called CXCL10 which triggers the activation of immune cells such as leukocytes. Once loaded with ImmunoBait, the red blood cells (which serve to transport oxygen around the body), hold on to their ammunition until they reach the intricate capillary beds of the lungs. In these narrow passages, the red blood cells are forced to squeeze through, where ImmunoBait is released. Antibodies that coat these nanoparticles cause them to attach to the lining of the blood vessels where they recruit immune cells to the scene to destroy tumor cells.

Anvay Ukidve, another researcher involved in the study published in Nature Biomedical Engineering, explained: “Lung metastases deplete certain kinds of chemokines from their local environment, which means the signal that should attract beneficial white blood cells to fight the tumor is gone.” 

“We hypothesized that providing that chemokine signal at the tumor site could help restore the body’s normal immune response and enable it to attack the tumors.”

 

Sources: Nature Biomedical Engineering, Wyss Institute.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
OCT 13, 2020
Immunology
Early Tips For Cell & Gene Therapy Regulatory Compliance
OCT 13, 2020
Early Tips For Cell & Gene Therapy Regulatory Compliance
Cell and gene therapies hold great promise for improved health outcomes. Now is the time to advance life-saving research ...
NOV 16, 2020
Immunology
Australian COVID-19 vaccine is promising and could be released next year
NOV 16, 2020
Australian COVID-19 vaccine is promising and could be released next year
Pharmaceutical companies worldwide are racing to develop a COVID-19 vaccine that will hopefully end this pandemic and he ...
NOV 25, 2020
Immunology
Another COVID-19 vaccine shows promising results!
NOV 25, 2020
Another COVID-19 vaccine shows promising results!
A week ago, another biotechnology company "Moderna" announced the preliminary results from its COVID-19 vaccin ...
JAN 12, 2021
Immunology
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
JAN 12, 2021
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
The first organ transplant—performed over 60 years ago—was a success because the donor and recipient were id ...
Loading Comments...